Honasa Consumer Shares Surge 52% Following Strategic Distribution Overhaul
According to Univest's market screen dated 17 September 2026, shares of Honasa Consumer Ltd—the parent company behind Mamaearth, The Derma Co., Aqualogica, and BBlunt—closed at approximately Rs 462.35, marking a 52.34% gain from Rs 303.50 a year earlier.

For a small-batch formulator tracking the category, the headline percentage is less informative than the path: a distribution overhaul in late 2024 triggered a quarterly loss, and six quarters of rebuilt margins pushed FY26 net profit to Rs 200.19 crore. The data points relevant to handmade skincare, facial cleansers, and men's grooming sit inside that recovery arc.
The Distribution Reset and the Earnings Rebuild
Honasa collapsed a two-layer super-stockist and sub-distributor model into a single direct-distributor layer across the top 50 cities in late 2024 under Project Neev. The accounting landed in the September 2024 quarter, reported on 14 November 2024. Sales returns and inventory write-down removed approximately Rs 63.52 crore from revenue, and the quarter swung to a Rs 18.71 crore net loss against a Rs 29.78 crore profit a year prior. Management had guided for roughly 150 basis points of margin impact, then conceded in-market credits went uncounted.
By the 13 November 2025 results, the rebuild was visible in the line items. Revenue of about Rs 538 crore grew 16.5%; EBITDA reached approximately Rs 48 crore and net profit Rs 39 crore, each coming off losses a year earlier. Focus categories now contribute over 75% of revenue. Mamaearth returned to profitability with a 123 basis point gain in the face cleansers segment, and The Derma Co. crossed Rs 750 crore in recurring revenue.
Why This Matters for Men's Grooming and Beard Care
On 12 December 2025, Honasa agreed to acquire 95% of BTM Ventures, owner of men's grooming brand Reginald Men, at an enterprise value near Rs 195 crore. Reginald Men had booked over Rs 70 crore of revenue at approximately 25% margin. The deal places Reginald inside a portfolio that already includes BBlunt and signals a category the parent treats as margin-accretive.
For a formulator evaluating the men's grooming shelf:
- A 25% margin on a Rs 70 crore top line indicates room in the segment for ingredient-costed products, not only low-margin private label.
- The 95% acquisition stake is consistent with category consolidation rather than brand incubation.
- Co-founder Varun Alagh bought 18.52 lakh shares at Rs 270 on 29 December 2025—approximately Rs 50 crore—lifting promoter holding to 35.54%, an insider signal during a recovery quarter.
Two adjacent data points from the same window are worth filing. The British Beauty Council published its 2026 Value of Beauty report on 14 September 2026, framing British consumer spending resilience and policy support for the high street. Separately, dsm-firmenich announced a Jakarta-based fragrance investment on 16 September 2026, expanding ingredient supply options for Southeast Asian formulators.
What a Small-Batch Producer Should Verify
The 52% gain is a stock outcome, not a formulation outcome. Treat it as a category signal and check the following on your own bench and ledger:
- Face cleansers category margin profile. If Mamaearth's 123 basis point gain reflects scale rather than formulation, artisan surfactants and shorter ingredient decks remain a different value proposition.
- Men's grooming acquisition activity. The Reginald Men deal values men's grooming at roughly 2.8× revenue. Comparable multiples for a beard care brand at the Rs 5–15 crore revenue band shift the exit math.
- Distribution cost in D2C channels. Project Neev's lesson—distribution layers can absorb margin without warning—applies to any brand scaling beyond its first 50 cities. Track return rates as a percentage of gross shipments.
- Insider buying during recovery. The December 2025 promoter purchase at Rs 270, against a Rs 462 close on 17 September 2026, is one data point; pattern across quarters is more telling.
The takeaway, stripped of market commentary: a commercial-scale operator rebuilt earnings by collapsing a distribution layer and absorbing the inventory cost up front. A small-batch formulator does not need to replicate that playbook, but the line items—return rates, inventory write-downs, and category-level margin contribution—are the same line items that determine whether a handmade line scales or stalls.